NCT04596098View on ClinicalTrials.gov

Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.

CompletedOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
SARS-CoV 2
Interventions
OTHER

Blood sampling

During a care-related blood sampling, patient will provide additional blood sample for research purpuse.

Trial Locations (1)

38043

UniversityGrenobleHospital, Grenoble

All Listed Sponsors
collaborator

Commissariat A L'energie Atomique

OTHER_GOV

lead

University Hospital, Grenoble

OTHER

NCT04596098 - Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine. | Biotech Hunter | Biotech Hunter